ProMetic Life Sciences Inc. Product Used In The Manufacture Of An FDA-Approved Biotherapeutic

ProMetic Life Sciences Inc. (TSX:PLI.SV) reported today that Halozyme Therapeutics, Inc. (Amex:HTI), a client of PLI’s subsidiary ProMetic BioSciences Ltd, has received U.S. Food and Drug Administration (FDA) approval for Hylenex recombinant (hyaluronidase human injection), for use as an adjuvant agent to increase the absorption and dispersion of other injected drugs. As part of its manufacturing process, Hylenex is purified using a proprietary synthetic-ligand affinity adsorbent manufactured by ProMetic BioSciences Ltd.